Especially, the inherited risk for ovarian cancer associated with pathogenic variants in BRCA1 and BRCA2 is of clinical relevance and has a direct impact on the survival of women treated for BRCA1/2-associated breast cancers [8]. This evidence concerns the gene BRCA2 and breast cancer.